786 results match your criteria: "the London School of Hygiene and Tropical Medicine[Affiliation]"

Objectives: COVID-19 vaccine was rolled out for the public in August 2021 in Zamfara state, Northen Nigeria. We determined the factors influencing COVID-19 vaccine acceptance.

Settings: We executed a community-based analytical cross-sectional study during the first 4 months of the second phase of the COVID-19 (Oxford/AstraZeneca) mass vaccination campaign in Zamfara state.

View Article and Find Full Text PDF

Efficacy, Safety, and Immunogenicity of the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Respiratory Syncytial Virus Prefusion F Protein Vaccine Trial.

Obstet Gynecol

January 2025

Children's Hospital Colorado, Aurora, Colorado; Vaccine Research and Development, Pfizer Inc, Pearl River, New York; the South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit and Wits Infectious Diseases and Oncology Research Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, and Famcru, Department of Paediatrics and Child Health, University of Stellenbosch, and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, SA-MRC Unit on Child and Adolescent Health, University of Cape Town, Cape Town, South Africa; Vaccines and Immunity Team, Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Fajara, the Gambia; Institute for International Health Charité, Universitätsmedizin, Berlin, Germany; Vaccine Research and Development, Pfizer Ltd, Marlow, United Kingdom; Instituto de Maternidad y Ginecología Nuestra Señora de Las Mercedes, San Miguel de Tucumán, and iTrials-Hospital Militar Central and iTrials, Buenos Aires, Argentina; Clinical Research Prime, Idaho Falls, Idaho; Boeson Research, Missoula, Montana; Meridian Clinical Research, Hastings, Nebraska; Asian Hospital and Medical Center, Manila, the Philippines; Department of Pediatrics, Spaarne Gasthuis, Haarlem and Hoofddorp, the Department of Pediatrics, Department of Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, and the ReSViNET Foundation, Zeist, the Netherlands; Meilahti Vaccine Research Center MeVac, Inflammation Center, University of Helsinki and Helsinki University Hospital, Helsinki, Finland; National Taiwan University Hospital, Taipei, Taiwan; the Department of Obstetrics and Gynecology, Sendai City Hospital, Sendai, Japan; Institute of Biomedical Sciences, University of Chile School of Medicine, Santiago, Chile; University of Otago and New Zealand Clinical Research, Christchurch, New Zealand; CHU Sainte-Justine, Montreal, Quebec, Canada; Hospital Moinhos de Vento and Pontifícia Universidade Católica RGS, Porto Alegre, Brazil; the Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark; Arké SMO S.A. de C.V., Mexico City, Mexico; University of Western Australia School of Medicine, Vaccine Trials Group, Wesfarmers Centre of Vaccines and Infectious Diseases, Telethon Kids Institute, and Perth Children's Hospital, Nedlands, Western Australia, and Vaccine Clinical Research, Pfizer Inc, Sydney, Australia; and Worldwide Safety, Pfizer Srl, Milan, Italy.

Objective: To evaluate descriptive efficacy data, exploratory immunogenicity data, and safety follow-up through study completion from the global, phase 3 MATISSE (Maternal Immunization Study for Safety and Efficacy) maternal vaccination trial of bivalent respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVpreF).

Methods: MATISSE was a phase 3, randomized, double-blinded, placebo-controlled trial. Healthy pregnant participants aged 49 years or younger at 24-36 weeks of gestation were randomized (1:1) to receive a single RSVpreF 120 micrograms or placebo dose.

View Article and Find Full Text PDF

Preterm Birth Frequency and Associated Outcomes From the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Trial of the Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine.

Obstet Gynecol

January 2025

South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit and the Wits Infectious Diseases and Oncology Research Institute, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, and the Department of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, SA-MRC Unit on Child and Adolescent Health, University of Cape Town, Cape Town, South Africa; the Vaccines and Immunity Team, Medical Research Council Unit The Gambia at the London School of Hygiene and Tropical Medicine, Fajara, the Gambia; the Institute for International Health Charité, Universitätsmedizin, Berlin, Germany; Children's Hospital Colorado, Aurora, Colorado; Vaccine Research and Development, Pfizer Inc, Pearl River, New York; Vaccine Research and Development, Pfizer Inc, Hurley, United Kingdom; Instituto de Maternidad y Ginecología Nuestra Señora de Las Mercedes, San Miguel de Tucumán, Argentina; iTrials-Hospital Militar Central, Buenos Aires, Argentina; the Stanford University School of Medicine, Palo Alto, California; the Department of Obstetrics and Gynecology, University of Washington, Seattle, Washington; and Worldwide Safety, Pfizer Srl, Milan, Italy.

Objective: To describe preterm birth frequency and newborn and infant outcomes overall and among preterm children in the MATISSE (Maternal Immunization Study for Safety and Efficacy) trial of maternal vaccination with bivalent respiratory syncytial virus (RSV) prefusion F protein-based vaccine (RSVpreF) to protect infants against severe RSV-associated illness.

Methods: MATISSE was a global, phase 3, randomized, double-blind trial. Pregnant individuals received single injections of RSVpreF or placebo.

View Article and Find Full Text PDF

Ebola Outbreak Response in the DRC with rVSV-ZEBOV-GP Ring Vaccination.

N Engl J Med

December 2024

From the Institut National de Recherche Biomédicale and Faculté de Médecine, Université de Kinshasa (J.-J.M., P.M.-K., S.M., S.A.-M.), and the Ministry of Public Health (S.H.B.M., N.T., E.M.M.) - both in Kinshasa, Democratic Republic of Congo; the Nuffield Department of Population Health, University of Oxford, Oxford (H.P., R.P.), and the London School of Hygiene and Tropical Medicine, London (C.H.R., M.M.) - both in the United Kingdom; University of Florida, Gainesville (I.M.L.); and the World Health Organization, Geneva (A.D., A.T., G.E., P.-S.G., X.R.B., M.N.K.Y., A.S.G., I.-S.F., P.S., M.J.R., A.M.H.-R.).

Background: At the beginning of the 2018-2020 outbreak of Ebola virus disease (EVD) in eastern Democratic Republic of Congo (DRC), no vaccine had been licensed. However, cluster-randomized evidence from Guinea in 2015 had indicated that ring vaccination around new cases (targeting contacts and contacts-of-contacts) with the use of single-dose live-replicating rVSV-ZEBOV-GP vaccine reduced EVD rates starting 10 days after vaccination. Thus, ring vaccination was added to the standard control measures for that outbreak.

View Article and Find Full Text PDF

Failure to rapidly diagnose tuberculosis disease (TB) and initiate treatment is a driving factor of TB as a leading cause of death in children. Current TB diagnostic assays have poor performance in children, and identifying novel non-sputum-based TB biomarkers to improve pediatric TB diagnosis is a global priority. We sought to develop a plasma biosignature for TB by probing the plasma proteome of 511 children stratified by TB diagnostic classification and HIV status from sites in four low- and middle-income countries, using high-throughput data-independent acquisition mass-spectrometry (DIA-PASEF-MS).

View Article and Find Full Text PDF

Progress towards hepatitis B virus (HBV) global elimination has been slow and most countries are far to reach the elimination targets set up by the World Health Organization (WHO). The burden of chronic hepatitis B is mainly bear by resource-limited countries where only a minority of people living with HBV are diagnosed and treated and international guidelines hardly applicable in real-life. In March 2024, the WHO released its revised guidelines for the prevention and management of chronic hepatitis B.

View Article and Find Full Text PDF

Exposure to Group A Streptococcus leads to a broad spectrum of disease and sequelae, as the bacterium employs a wide range of virulence factors to facilitate colonization of the host, propagation and onward transmission, disrupting both innate and adaptive immune responses. The protease SpyCEP has a crucial role in contributing to bacterial immune evasion by impairing neutrophil recruitment and killing of bacteria through the cleavage of interleukin-8 (IL-8). Given this critical function, SpyCEP represents a key vaccine antigen and quantifying functional anti-SpyCEP antibodies represents not only an important marker of vaccine efficacy, but also a tool to dissect the natural immune response.

View Article and Find Full Text PDF
Article Synopsis
  • There is a need for more research on neonatal behavior that applies to diverse global populations, but few appropriate assessment measures exist for use from birth.
  • The Neonatal Behavioural Assessment Scale (NBAS) was piloted in rural Gambia and showed great utility, leading to adaptations tailored to the local environment.
  • When comparing NBAS results between infants in the UK and The Gambia, findings indicated fewer state changes in Gambian infants and revealed associations with perinatal factors like pregnancy anxiety, suggesting cultural contexts impact early neurobehavioral development.
View Article and Find Full Text PDF

Unlabelled: Timely diagnostic tools are needed to improve antibiotic treatment. Pairing metagenomic sequencing with genomic neighbor typing algorithms may support rapid clinically actionable results. We created resistance-associated sequence elements (RASE) databases for and .

View Article and Find Full Text PDF

The GeneXpert HBV Viral Load test is a simplified tool to scale up screening and HBV monitoring in resource-limited settings, where HBV is endemic and where molecular techniques to quantify HBV DNA are expensive and scarce. However, the accuracy of field diagnostics compared to gold standard assays in HBV-endemic African countries has not been well understood. We aim to validate the diagnostic performance of the GeneXpert HBV Viral Load test in freshly collected and stored plasma and dried blood spot (DBS) samples to assess turn-around-time (TAT) for sample processing and treatment initiation, to map GeneXpert machines and to determine limitations to its use in The Gambia.

View Article and Find Full Text PDF

: The Measles-Rubella Microarray Patch (MR-MAP) is an important technology that is expected to reduce coverage and equity gaps for measles-containing vaccines (MCVs), reach zero-dose children, and contribute to elimination of measles and rubella. MR-MAPs are anticipated to be easier to deploy programmatically and could be delivered by lesser-trained health workers, thereby increasing immunization coverage. The most advanced MR-MAP has reached clinical proof-of-concept through a Phase I/II trial in the target population of infants and young children.

View Article and Find Full Text PDF

Background: Costing and financing systematic implementation are recognized barriers to human immunodeficiency virus (HIV) prevention. In the absence of empiric implementation and economic data, perspectives from international stakeholders involved in developing and supporting daily oral pre-exposure prophylaxis (PrEP) policy, and programs can provide critical insights for developing costed plans to support and accelerate the rollout of novel long-acting PrEP (LA-PrEP) methods, such as the monthly dapivirine vaginal ring (PrEP ring).

Methods: We interviewed stakeholders from purposively selected international organizations about anticipated PrEP-ring implementation costs, evidence gaps and key process steps for developing a costed rollout plan template (CRPT).

View Article and Find Full Text PDF
Article Synopsis
  • Sustainable domestic health financing is crucial for achieving Universal Health Coverage (UHC) in Low- and Middle-Income Countries, and this study focuses on Senegal's health financing sources.
  • The research involves interviews with 32 key stakeholders and analysis of various data to explore how development partners influence domestic health contributions through mechanisms like setting standards, lobbying, providing advice, and external financing.
  • While development partners aim to enhance equity by increasing government tax contributions and expanding Community-Based Health Insurance, challenges related to equity remain, prompting a need for further examination of the impact of international creditors on domestic health financing.
View Article and Find Full Text PDF

Background: Maternal mental illness (MMI) affects almost a quarter of mothers and may impact a child's development and physical health. It remains unclear whether MMI is associated with altered utilization of vaccination services. Understanding this association could help to identify families in need of additional support.

View Article and Find Full Text PDF

Vitamin D dysregulation can occur in people living with HIV, disrupting calcium homeostasis, and bone turnover. We aimed to investigate the potential mechanisms by which vitamin D regulates bone turnover in adolescents living with perinatally-acquired HIV (ALWH) in Southern Africa. A pre-planned secondary analysis was performed of baseline data from the vitamin D for adolescents with HIV to reduce musculoskeletal morbidity and immunopathology trial (PACTR20200989766029) which enrolled ALWH (11-19 yr) taking antiretroviral therapy for ≥6 mo, and recorded socio-demographic, clinical and dietary data.

View Article and Find Full Text PDF

Background: Arthropod vectors feeding on the blood of individuals treated with ivermectin have substantially increased mortality. Whether this effect will translate into a useful tool for reducing malaria burden at scale is not clear. Our trial aimed to assess whether using ivermectin as an adjunct to mass drug administration (MDA) with dihydroartemisinin-piperaquine would further reduce malaria prevalence.

View Article and Find Full Text PDF

Innovative diagnostic technologies: navigating regulatory frameworks through advances, challenges, and future prospects.

Lancet Digit Health

December 2024

West African Centre for Cell Biology of Infectious Pathogens, College of Basic and Applied Sciences, University of Ghana, Legon, Accra, Ghana.

Diagnostic tools are key to guiding patient management and informing public health policies to control infectious diseases. However, many diseases still do not have effective diagnostics and much of the global population faces restricted access to reliable, affordable testing. This limitation underscores the urgent need for innovation to enhance diagnostic availability and effectiveness.

View Article and Find Full Text PDF

Background: Centralising prostate cancer surgical and radiotherapy services, requires some patients to travel longer to access treatment, but its impact on actual treatment utilisation and outcomes is unknown.

Methods: Using national cancer registry records linked to administrative hospital data, we identified all patients with high risk and locally advanced prostate cancer diagnosed between 1 April 2019 and 31 March 2020 in the English National Health Service (n = 15,971). Estimated travel times from the patient residential areas to the nearest hospital providing surgery or radiotherapy were estimated for journeys by car and by public transport.

View Article and Find Full Text PDF

Clinical outcomes of untreated adults living with chronic hepatitis B in The Gambia: an analysis of data from the prospective PROLIFICA cohort study.

Lancet Gastroenterol Hepatol

December 2024

Medical Research Council Unit, The Gambia at the London School of Hygiene and Tropical Medicine, Bakau, The Gambia; Department of Metabolism, Digestion and Reproduction, Division of Digestive Diseases, Liver Unit, Imperial College London, St Mary's Hospital, London, UK. Electronic address:

Background: Expanding antiviral therapy to people with chronic hepatitis B virus (HBV) infection who are ineligible to receive treatment under current international criteria has been increasingly debated. Evidence to support this approach is scarce, especially in Africa. We aimed to address this knowledge gap by analysing the clinical outcomes of people with chronic hepatitis B in The Gambia who were untreated and ineligible for antiviral therapy at diagnosis.

View Article and Find Full Text PDF

Evaluating methods for identifying and quantifying co-colonization using next-generation sequencing data.

Microbiol Spectr

November 2024

Faculty of Epidemiology and Population Health, Department of Infectious Disease Epidemiology, The London School of Hygiene and Tropical Medicine, London, United Kingdom.

Detection of multiple pneumococcal serotype carriage can enhance monitoring of pneumococcal vaccine impact, particularly among high-burden childhood populations. We assessed methods for identifying co-carriage of pneumococcal serotypes from whole-genome sequences. Twenty-four nasopharyngeal samples were collected during community carriage surveillance from healthy children in Blantyre, Malawi, which were then serotyped by microarray.

View Article and Find Full Text PDF
Article Synopsis
  • The study investigated the prevalence and characteristics of human metapneumovirus (hMPV) in children with severe pneumonia across seven African and Asian countries, finding a significant correlation between hMPV and pneumonia cases compared to community controls.
  • HMPV was more frequently detected in hospitalized pneumonia cases (6.9%) than in controls (2.3%), with a notable negative association with RSV and a positive association with bacterial infections.
  • The majority of hMPV-positive cases were infants under one year, with low mortality rates similar to those of RSV-positive cases, indicating that hMPV pneumonia is challenging to distinguish from RSV pneumonia in clinical settings.
View Article and Find Full Text PDF

Multi-level determinants of timely routine childhood vaccinations in The Gambia: Findings from a nationwide analysis.

Vaccine

January 2025

Vaccines and Immunity Theme, MRC Unit The Gambia a London School of Hygiene and Tropical Medicine, Fajara, the Gambia; Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom; Centre for Global Health, Charité Universitatsmedizin Berlin, Germany.

Introduction: Achieving the ambitious goals of the Immunisation Agenda 2030 (IA2030) requires a deeper understanding of factors influencing under-vaccination, including timely vaccination. This study investigates the demand- and supply-side determinants influencing the timely uptake of key childhood vaccines scheduled throughout the first year of life in The Gambia.

Methods: We used two nationally-representative datasets: the 2019-20 Gambian Demographic and Health Survey and the 2019 national immunisation facility mapping.

View Article and Find Full Text PDF

Towards integrated malaria molecular surveillance in Africa.

Trends Parasitol

November 2024

National Institute for Medical Research, Dar es Salaam, Tanzania; Harvard T.H. Chan School of Public Health, Boston, MA, USA; Kampala International University in Tanzania, Dar es Salaam, Tanzania. Electronic address:

Integrated malaria molecular surveillance (iMMS) systems are essential for Africa's expanding malaria genomics initiatives. Here we highlight a few initiatives and demonstrate how iMMS can support evidence-based decisions and policies for National Malaria Programs and other malaria control stakeholders. We conclude with key considerations for advancing these malaria genomics initiatives towards sustainable iMMS.

View Article and Find Full Text PDF

Predictive gene expression signature diagnoses neonatal sepsis before clinical presentation.

EBioMedicine

December 2024

Department of Molecular Biology and Biochemistry, Simon Fraser University, Burnaby, Canada. Electronic address:

Article Synopsis
  • Neonatal sepsis is a serious condition with vague symptoms, making early diagnosis challenging; researchers aimed to identify gene expression biomarkers at birth to improve early detection.
  • In a study of 720 healthy full-term newborns, they compared gene expression data from those later hospitalized for early-onset sepsis (EOS) and others who remained healthy, identifying significant genetic differences.
  • A 4-gene signature (HSPH1, BORA, NCAPG2, PRIM1) was developed, showing high predictive accuracy for EOS at birth, indicating that even healthy-appearing infants may already exhibit signs of future sepsis through gene expression changes.
View Article and Find Full Text PDF

Background: Undernutrition during the early years of life has a harmful and irreversible impact on child growth and cognitive development. Many of the interventions tested to improve outcomes across infancy have had disappointing or inconsistent impact, a common feature being the absence of any attempt to provide nutritional supplements to infants during the first six months. With increasing evidence of micronutrient deficiencies in this age group, alongside strong evidence that growth and developmental deficits begin before six months, a renewed focus on the micronutrient status of infants is required.

View Article and Find Full Text PDF